Physician profile
Antoine Kassis
NPI 1477627875
$2,916.34
in general payments reported to CMS, 2019-2025
27 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $418 · 2021: $417 · 2022: $421 · 2023: $493 · 2024: $419 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $801.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $307.33 | 2019-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $266.75 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.95 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $201.48 | 2019-2024 | |
| Lilly USA, LLC | $171.24 | 2022-2024 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $143.37 | 2019-2022 | |
| Exact Sciences Corporation | $107.63 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $99.78 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $85.70 | 2019-2022 | |
| Evoke Pharma, INC. | $68.72 | 2020-2021 | |
| Abbott Laboratories | $42.14 | 2022-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.40 | 2020-2022 | |
| Inspire Medical Systems, INC. | $34.40 | 2025 | Inspire |
| Shield Therapeutics INC | $32.97 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.43 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $28.39 | 2022-2025 | Zoryve |
| Global Blood Therapeutics, INC. | $27.81 | 2020-2021 | |
| Dexcom, INC. | $24.30 | 2022 | |
| Astellas Pharma US INC | $21.88 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $21.84 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.83 | 2021 | |
| Mayne Pharma Commercial LLC | $20.42 | 2025 | |
| Arbor Pharmaceuticals, INC. | $16.02 | 2020 | |
| Bausch Health US, LLC | $15.25 | 2020 | |
| Urgo Medical North America, LLC | $14.23 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Xeris Pharmaceuticals, INC. | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoine Kassis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.